Literature DB >> 5420605

Clinical features and treatment of pre-ulcerative Buruli lesions (Mycobacterium ulcerans infection). Report II of the Uganda Buruli Group.

.   

Abstract

At Kinyara, and in other areas of Uganda, 250 patients with pre-ulcerative Buruli lesions (Myco. ulcerans infection, have been seen over the past three years. The clinical feature of the pre-ulcerative stage of the disease are painless nodules, usually occurring singly on the legs or forearms. As the nodule can grow rapidly to become an extensive fulminating lesion, early recognition of the nodule and an appreciation of its significance by both doctor and patient are essential. Excision of the nodule is simple and usually curative, thus preventing ulcers developing and requiring prolonged hospital treatment.

Entities:  

Mesh:

Year:  1970        PMID: 5420605      PMCID: PMC1700267     

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


  6 in total

1.  MYCOBACTERIAL SKIN ULCERS IN UGANDA: DESCRIPTION OF A NEW MYCOBACTERIUM (MYCOBACTERIUM BURULI).

Authors:  J K CLANCEY
Journal:  J Pathol Bacteriol       Date:  1964-07

2.  TREATMENT OF MYCOBACTERIAL SKIN ULCERS IN UGANDA WITH A RIMINOPHENAZINE DERIVATIVE (B.663).

Authors:  H F LUNN; R J REE
Journal:  Lancet       Date:  1964-02-01       Impact factor: 79.321

3.  BURULI (MYCOBACTERIAL) ULCERATION IN UGANDA. (A NEW FOCUS OF BURULI ULCER IN MADI DISTRICT, UGANDA): REPORT OF A FIELD STUDY.

Authors:  H F LUNN; D H CONNOR; N E WILKS; G R BARNLEY; F KAMUNVI; J K CLANCEY; J D BEE
Journal:  East Afr Med J       Date:  1965-06

4.  Mycobacterial skin ulcers in Uganda.

Authors:  J K CLANCEY; O G DODGE; H F LUNN; M L ODUORI
Journal:  Lancet       Date:  1961-10-28       Impact factor: 79.321

5.  Mycobacterium ulcerans infection (with comments on pathogenesis).

Authors:  D H Connor; H F Lunn
Journal:  Int J Lepr       Date:  1965 Jul-Sep

6.  Mycobacterium ulcerans infection. Clinical and bacteriological study of the first cases recognized in South East Asia.

Authors:  J H Pettit; N J Marchette; R J Rees
Journal:  Br J Dermatol       Date:  1966-04       Impact factor: 9.302

  6 in total
  5 in total

Review 1.  [Mycobacterium ulcerans infection in man (Baruli-ulcer)].

Authors:  G Kieninger; G E Schubert; U Ullmann; W Höfler
Journal:  Infection       Date:  1973       Impact factor: 3.553

2.  Cytokine mRNA expression in Mycobacterium ulcerans-infected human skin and correlation with local inflammatory response.

Authors:  R Phillips; C Horsfield; J Mangan; K Laing; S Etuaful; P Awuah; K Nyarko; F Osei-Sarpong; P Butcher; S Lucas; M Wansbrough-Jones
Journal:  Infect Immun       Date:  2006-05       Impact factor: 3.441

3.  Mapping suitability for Buruli ulcer at fine spatial scales across Africa: A modelling study.

Authors:  Hope Simpson; Earnest Njih Tabah; Richard O Phillips; Michael Frimpong; Issaka Maman; Edwin Ampadu; Joseph Timothy; Paul Saunderson; Rachel L Pullan; Jorge Cano
Journal:  PLoS Negl Trop Dis       Date:  2021-03-03

Review 4.  Drugs for treating Buruli ulcer (Mycobacterium ulcerans disease).

Authors:  Rie R Yotsu; Marty Richardson; Norihisa Ishii
Journal:  Cochrane Database Syst Rev       Date:  2018-08-23

5.  Histopathologic features of Mycobacterium ulcerans infection.

Authors:  Jeannette Guarner; Jeanine Bartlett; Ellen A Spotts Whitney; Pratima L Raghunathan; Ymkje Stienstra; Kwame Asamoa; Samuel Etuaful; Erasmus Klutse; Eric Quarshie; Tjip S van der Werf; Winette T A van der Graaf; C Harold King; David A Ashford
Journal:  Emerg Infect Dis       Date:  2003-06       Impact factor: 6.883

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.